查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2030145

非處方藥市場－全球產業規模、佔有率、趨勢、機會與預測：按產品、劑型、地區和競爭格局分類，2021-2031年

Over the Counter Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Dosage Form, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球非處方藥市場預計將從 2025 年的 113.2 億美元成長到 2031 年的 173.5 億美元，複合年成長率為 7.38%。

非處方藥（OTC）是指消費者無需醫生處方箋即可直接購買的藥品，主要用於自我診斷和治療輕微健康問題。該市場擴張的主要原因是消費者越來越偏好自我治療、健康意識不斷提高以及全球人口老化。此外，非處方藥的可近性和對經濟實惠的替代品的需求也是推動市場成長的重要因素。歐洲自我護理產業協會（AESGP）的一份報告也印證了這個趨勢，報告指出，到2024年，歐洲非處方藥的銷售量將達到47億盒。

市場概覽
預測期 2027-2031
市場規模：2025年 113.2億美元
市場規模：2031年 173.5億美元
複合年成長率：2026-2031年 7.38%
成長最快的細分市場 咳嗽
最大的市場 北美洲

儘管存在這些積極趨勢，但全球成藥市場在應對複雜且不斷變化的法規環境方面仍面臨許多挑戰。成功駕馭此框架需要嚴格遵守合規標準，並建立完善的藥品安全監測體系，以確保產品安全和消費者合理使用。

市場促進因素

推動市場成長的主要動力之一是消費者越來越傾向於自行解決輕微的健康問題和疾病。這種轉變源自於消費者對非處方箋藥的便利性、可近性和經濟性的偏好，而傳統處方箋藥則較受青睞。透過尋求簡單經濟的常見健康問題解決方案，消費者在自身健康管理中扮演著更積極的角色，從而擴大了非處方藥（OTC）的目標市場。為了佐證這項向自我護理的廣泛轉變，美國消費者保健產品協會（CHPA）2026年2月的一項調查顯示，46%的美國成年人在過去一周內使用過成藥。

此外，全球人口老化是推動非成藥）市場成長要素。隨著全球人口老化，慢性病和與老齡化相關的健康問題的發生率必然增加，但其中許多疾病可以透過非處方藥物得到有效控制。老年人經常尋求便捷的自我護理方案來治療日常疾病並維持生活品質，這推動了成藥的消費。世界衛生組織（WHO）在2025年2月發布的報告強調了這一人口結構變化，報告指出，全球60歲及以上人口將從2023年的11億增至2030年的14億，這意味著潛在的非處方藥消費群體將顯著成長。同時，歐洲自我護理產業協會在2025年7月指出，2024年歐洲10個國家至少有13種處方藥轉為非處方藥，進一步擴大了非處方治療的選擇範圍。

市場挑戰

全球非處方藥市場面臨的一大障礙是應對複雜且不斷變化的法規環境。製造商必須嚴格遵守這些詳盡且定期修訂的監管框架，這需要對產品研發、嚴格的測試和全面的文件編制進行大量投資，以滿足各種區域和國際標準。這種動態的法規環境給產業資源帶來了沉重負擔，常常導致產品上市延遲，並因持續的調整和核准流程而增加營運成本。

此外，全面的藥物警戒要求增加了營運成本，尤其是在企業必須遵守世界各地不同的監管要求的情況下。這種複雜的監管網路限制了產品的可近性，阻礙了創新產品快速惠及大眾，直接阻礙了市場成長。全球自我護理聯盟 (GSF) 的預測也印證了這個問題：到 2025 年，全球約有 20 億人將無法獲得必要的非處方藥 (OTC)。這種短缺主要是由於監管能力的不足。這些瓶頸縮小了非處方藥的潛在消費群體，最終阻礙了自我護理產品的廣泛應用和全球供應。

市場趨勢

全球非處方藥（OTC）市場正受到分銷網路數位化的顯著影響，這從根本上改變了人們獲取非處方藥的方式。這項變更的關鍵特徵是網路藥局和電商網站的快速成長，它們提供了無與倫比的便利性和更廣泛的產品選擇。消費者越來越依賴線上資源進行產品研究、比較和直接購買，從而簡化了獲取自我護理保健藥物的流程。林肯國際有限責任公司（Lincoln International LLC）的報告《2025年非處方藥趨勢與併購》強調了數位商務在該領域日益成長的價值，並預測到2025年，美國線上成藥銷售額將達到44.6億美元。

一個更顯著的趨勢是，在消費者偏好高度個人化和客製化的健康解決方案的推動下，人們越來越關注創新配方和成分。這包括開發尖端的給藥機制、整合經科學驗證的天然成分，以及針對特定族群和獨特健康問題量身定做的產品配方。這波創新浪潮正超越傳統的症狀管理，轉向全面且具預防性的健康產品，進而提高療效和使用者滿意度。例如，《美國新聞與世界報道》在2025年5月發表了報導題為「美國新聞發布2025-2026年度最佳成藥和保健品」的文章，指出最新排名新增了12個非處方藥類別，凸顯了現有產品的持續多元化。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球非處方藥市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類別（咳嗽、感冒和流感；維生素、礦物質和補充劑；止痛藥；胃腸道藥物；皮膚科產品；其他）
    • 劑型（片劑、膠囊、液體/溶液、乳膏/洗劑/軟膏、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美非處方藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲非處方藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區非處方藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲非處方藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲非處方藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球非處方藥市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Sanofi SA
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Perrigo Company plc
  • Reckitt Benckiser Group PLC
  • Takeda Pharmaceutical Company Ltd
  • Boehringer Ingelheim International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 5054

The Global Over the Counter (OTC) Drugs Market is anticipated to expand from USD 11.32 billion in 2025 to USD 17.35 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 7.38%. OTC drugs are pharmaceutical items available directly to consumers without a doctor's prescription, designed for the self-diagnosis and treatment of minor health issues. This market expansion is largely fueled by a growing consumer preference for self-medication, heightened health awareness, and an increasing aging population worldwide. Additionally, the ease of accessibility and the demand for economical substitutes to prescription drugs play a crucial role in propelling market growth. Demonstrating this trend, the Association of the European Self-Care Industry (AESGP) reported that 4.7 billion packages of non-prescription medications were purchased across Europe in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 11.32 Billion
Market Size 2031USD 17.35 Billion
CAGR 2026-20317.38%
Fastest Growing SegmentCough
Largest MarketNorth America

Despite this positive trajectory, the worldwide OTC drugs market encounters a significant hurdle in managing intricate and constantly changing regulatory environments. Successfully navigating these frameworks requires strict adherence to compliance standards and comprehensive pharmacovigilance to guarantee the safety of products and their proper use by consumers.

Market Driver

A primary catalyst for market growth is the rising consumer inclination toward self-medication, with people increasingly choosing to independently address minor health issues and ailments. This shift is driven by a preference for the convenience, widespread availability, and affordability that non-prescription options offer compared to conventional prescription healthcare. By seeking accessible and economical remedies for common health problems, consumers are assuming a more active role in managing their personal well-being, which in turn broadens the target demographic for OTC products. Highlighting this widespread shift toward self-care, a February 2026 study by the Consumer Healthcare Products Association revealed that 46% of adults in the United States had utilized an OTC medicine within a single week.

Furthermore, the expanding elderly population worldwide acts as a major driver for the OTC drugs market. An aging global demographic naturally leads to a higher incidence of chronic illnesses and age-related health conditions, many of which are highly manageable using non-prescription items. Seniors frequently look for accessible self-care solutions to treat everyday ailments and preserve their overall quality of life, thereby driving up the consumption of OTC remedies. Emphasizing this demographic shift, the World Health Organization reported in February 2025 that the global population aged 60 and above is expected to grow from 1.1 billion in 2023 to 1.4 billion by 2030, creating a massive influx of potential OTC consumers. Concurrently, the Association of the European Self-Care Industry noted in July 2025 that 2024 saw at least thirteen prescription-to-OTC status changes across ten European nations, further expanding the variety of available non-prescription therapies.

Market Challenge

A major obstacle confronting the global Over-the-Counter (OTC) drugs market is the navigation of complicated and continuously shifting regulatory environments. Manufacturers must maintain strict compliance with these detailed and regularly revised frameworks, which demands heavy financial commitments toward product development, rigorous testing, and comprehensive documentation to satisfy a wide array of local and international standards. Such a fluid regulatory climate heavily taxes industry resources, frequently resulting in postponed product launches and elevated operational expenses related to ongoing adjustments and approval procedures.

Additionally, the requirement for comprehensive pharmacovigilance increases operational costs, especially when companies must adhere to differing mandates across various global territories. This intricate web of regulations directly stymies market growth by limiting the availability of products and preventing fresh innovations from swiftly reaching the public. Illustrating this issue, the Global Self-Care Federation (GSF) stated in 2025 that approximately 2 billion people worldwide were without access to necessary non-prescription medications, a shortfall largely attributed to constraints in regulatory capacity. These bottlenecks shrink the prospective consumer base for OTC offerings, which ultimately hinders the broader advancement and global availability of self-care remedies.

Market Trends

The worldwide Over-the-Counter (OTC) drugs market is heavily impacted by the digitization of distribution networks, which is completely transforming the way individuals acquire non-prescription medicines. This transition is characterized by the swift growth of internet-based pharmacies and e-commerce websites, providing unmatched ease of use and a wider selection of products. Buyers are depending more and more on online resources to research, compare, and purchase items directly, thereby simplifying the way they obtain self-care treatments. Highlighting the escalating value of digital commerce in the sector, Lincoln International LLC's 'Over-the-Counter Drug Trends and M&A in 2025' report indicated that online OTC drug revenues in the U.S. were forecasted to hit $4.46 billion in 2025.

A further crucial trend is the heightened focus on innovative formulations and ingredients, spurred by changing consumer preferences for highly specific and customized health remedies. This movement includes the engineering of cutting-edge delivery mechanisms, the integration of scientifically proven natural components, and the formulation of goods designed for particular demographics or distinct health issues. This wave of innovation goes beyond standard symptom management, shifting toward comprehensive and preventative wellness products that improve both effectiveness and user satisfaction. Demonstrating this active environment of product advancement, a May 2025 article by U.S. News & World Report titled 'U.S. News releases the 2025-2026 Best OTC Medicine & Health Products' noted the addition of 12 novel over-the-counter categories for their latest rankings, emphasizing the ongoing diversification of available items.

Key Market Players

  • Sanofi SA
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Perrigo Company plc
  • Reckitt Benckiser Group PLC
  • Takeda Pharmaceutical Company Ltd
  • Boehringer Ingelheim International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Ltd.

Report Scope

In this report, the Global Over the Counter (OTC) Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Over the Counter (OTC) Drugs Market, By Product

  • Cough
  • Cold & Flu
  • Vitamins
  • Mineral
  • & Supplements (VMS)
  • Analgesics
  • Gastrointestinal Products
  • Dermatology Products
  • Others

Over the Counter (OTC) Drugs Market, By Dosage Form

  • Tablets
  • Capsules
  • Liquids & Solutions
  • Cream/Lotion/Ointments
  • Others

Over the Counter (OTC) Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Over the Counter (OTC) Drugs Market.

Available Customizations:

Global Over the Counter (OTC) Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Over the Counter (OTC) Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Cough, Cold & Flu, Vitamins, Mineral, & Supplements (VMS), Analgesics, Gastrointestinal Products, Dermatology Products, Others)
    • 5.2.2. By Dosage Form (Tablets, Capsules, Liquids & Solutions, Cream/Lotion/Ointments, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Over the Counter (OTC) Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Dosage Form
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Over the Counter (OTC) Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Dosage Form
    • 6.3.2. Canada Over the Counter (OTC) Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Dosage Form
    • 6.3.3. Mexico Over the Counter (OTC) Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Dosage Form

7. Europe Over the Counter (OTC) Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Dosage Form
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Over the Counter (OTC) Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Dosage Form
    • 7.3.2. France Over the Counter (OTC) Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Dosage Form
    • 7.3.3. United Kingdom Over the Counter (OTC) Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Dosage Form
    • 7.3.4. Italy Over the Counter (OTC) Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Dosage Form
    • 7.3.5. Spain Over the Counter (OTC) Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Dosage Form

8. Asia Pacific Over the Counter (OTC) Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Dosage Form
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Over the Counter (OTC) Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Dosage Form
    • 8.3.2. India Over the Counter (OTC) Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Dosage Form
    • 8.3.3. Japan Over the Counter (OTC) Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Dosage Form
    • 8.3.4. South Korea Over the Counter (OTC) Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Dosage Form
    • 8.3.5. Australia Over the Counter (OTC) Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Dosage Form

9. Middle East & Africa Over the Counter (OTC) Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Dosage Form
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Over the Counter (OTC) Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Dosage Form
    • 9.3.2. UAE Over the Counter (OTC) Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Dosage Form
    • 9.3.3. South Africa Over the Counter (OTC) Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Dosage Form

10. South America Over the Counter (OTC) Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Dosage Form
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Over the Counter (OTC) Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Dosage Form
    • 10.3.2. Colombia Over the Counter (OTC) Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Dosage Form
    • 10.3.3. Argentina Over the Counter (OTC) Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Dosage Form

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Over the Counter (OTC) Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Sanofi SA
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. GlaxoSmithKline plc
  • 15.4. Perrigo Company plc
  • 15.5. Reckitt Benckiser Group PLC
  • 15.6. Takeda Pharmaceutical Company Ltd
  • 15.7. Boehringer Ingelheim International GmbH
  • 15.8. Sun Pharmaceutical Industries Ltd.
  • 15.9. Teva Pharmaceutical Industries Ltd.
  • 15.10. Glenmark Pharmaceuticals Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer